Leukocytes and their cytokines play important regulatory roles in all aspects of tumor development; therefore the anti-inflammation drugs targeting AMPK activation may play a more meaningful role for the treatment of cancer-associated inflammation. This evidence concerns the gene PRKAA1 and neoplasm.